Exelixis
EXEL
#1888
Rank
A$15.39 B
Marketcap
A$60.60
Share price
-1.75%
Change (1 day)
0.43%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): A$4.41

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$4.01. In 2023 the company made an earnings per share (EPS) of A$0.91 an increase over its 2022 EPS that were of A$0.79.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$4.41
2023A$0.9114.61%
2022A$0.79-22.97%
2021A$1.03100%
2020A$0.51-65.09%
2019A$1.47-53.91%
2018A$3.19333.96%
2017A$0.74-260.61%
2016A-$0.46-58.75%
2015A-$1.11-42.45%
2014A-$1.935.3%
2013A-$1.83

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$15.45 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.89-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$19.88 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.86-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$10.14 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$4.80 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$5.23 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$5.09-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.17-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA